Clinical trials: Astrocytoma, Malignant
Malignant Glioma, Astrocytoma
Nivolumab With DC Vaccines for Recurrent Brain Tumors
Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until…
- Conditions
- Malignant Glioma, Astrocytoma, Glioblastoma
- Trial name
- AVERT (NCT02529072)
- Testing
- nivolumab, DC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Gary Archer Ph.D.
Glioblastoma, Gliosarcoma
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Primary Objective to estimate 6-month progression free survival probability of patients with recurrent malignant glioma treated with Etoposide + Bevacizumab.
- Trial name
- NCT00612430
- Testing
- Bevacizumab and Etoposide
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Cytomegalovirus Infection
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue.
- Trial name
- NCT00400322
- Testing
- Valganciclovir (Valcyte)
- Where
- 3 sites in Sweden
- Volunteers
- 42 people
- Sponsor
- Karolinska Institutet
Glioblastoma Multiforme
TRC105 for Recurrent Glioblastoma
Background: Glioblastoma is an aggressive type of brain cancer that often resists treatment. TRC105 is an experimental drug that blocks the growth of new blood vessels.
- Trial name
- NCT01778530
- Testing
- TRC105
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Lymphoma
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT01273090
- Testing
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Children's Oncology Group
Recurrent Malignant Gliomas
Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
The drug LBH589 (panobinostat) is an experimental (investigational) drug that is being tested for recurrent (returning) malignant gliomas. An investigational drug is one that has not been approved by the U.S.
- Trial name
- NCT00848523
- Testing
- Panobinostat
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Neurological Surgery, P.C.
Malignant Glioma
Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
The objective of this study is to determine the survival status of patients enrolled in study GLI01S (all-case observational study).
- Trial name
- NCT02300506
- Testing
- No intervention
- Where
- 2 sites in Japan
- Volunteers
- 507 people
- Sponsor
- Eisai Co., Ltd.
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not…
- Conditions
- Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
- Trial name
- NCT00102648
- Testing
- Lonafarnib, Temozolomide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Cancer, MALIGNANT GLIOMA
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
The best dose of radiation to be given with bevacizumab is currently unknown. This study will use higher doses of radiation with bevacizumab than have been used before.
- Conditions
- Brain Cancer, MALIGNANT GLIOMA, Glioblastoma, Anaplastic Astrocytoma (AA)
- Trial name
- NCT01392209
- Testing
- Bevacizumab & Stereotactic Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse…
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma
- Trial name
- NCT07468136
- Testing
- Biospecimen Collection, Eflornithine, Lumbar Puncture
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Brain and Central Nervous System Tumors
Karenitecin in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of karenitecin in treating patients who have recurrent…
- Trial name
- NCT00014521
- Testing
- karenitecin
- Where
- 8 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Glioblastoma Multiforme, Chemoradiation
Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation
Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
- Trial name
- NCT03225300
- Testing
- Simultaneous integrated boost
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taichung Veterans General Hospital
Malignant Glioma, Glioblastoma Multiforme
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
The primary objective of the study is to use 24 week survival to assess the efficacy of the combination of Gliadel followed by Avastin and irinotecan in the treatment of grade IV malignant glioma patients following surgical…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Gliosarcoma
- Trial name
- NCT00735436
- Testing
- Gliadel/Avastin/CPT-11
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed…
- Trial name
- NCT00003464
- Testing
- temozolomide, radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Duke University
Recurrent Glioblastoma, Recurrent Malignant Glioma
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is…
- Conditions
- Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
- Trial name
- NCT04214392
- Testing
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- City of Hope Medical Center
Glioblastoma, Glioblastoma With Primitive Neuronal Component
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
This phase II trial studies how well whole brain radiation therapy works with standard temozolomide chemo-radiotherapy and plerixafor in treating patients with glioblastoma (brain tumor).
- Conditions
- Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma
- Trial name
- NCT03746080
- Testing
- Plerixafor, Temozolomide, Whole-Brain Radiotherapy (WBRT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Lawrence D Recht
Recurrent or Progressive Malignant Glioma
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma.
- Trial name
- NCT00539344
- Testing
- ANG1005
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Angiochem Inc
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Brain and Central Nervous System Tumors
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of lapatinib and to see how well it works in…
- Trial name
- NCT00099060
- Testing
- lapatinib ditosylate
- Where
- 6 sites in Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)